Saturday, April 20, 2024
4/20/2024
The application of new computerized methods of data analysis to vast collections of medical, biological, and other data is emerging as a central feature of a broad vision of precision medicine (PM) in which systems based on artificial intelligence (AI) assist clinicians in treatment, diagnosis, or prognosis. The use of AI to analyze big data for clinical decision-making opens up a new domain for ELSI inquiry to address a possible future when the implications of genetics and genomics become embedded into algorithms, pervasive yet implicit and difficult to identify. Thus, an important target of inquiry is the development and developers of these algorithms. There are three distinctive features of the application of AI, and in particular machine learning (ML), to the domain of PM that create the need for ELSI inquiry. First, the process of developing ML-based systems for PM goals is technically and organizationally complex. Thus, members of development teams will likely have different expertise and assumptions about norms, responsibilities, and regulation. Second, machine learning does not solely operate through predetermined rules, and is thus difficult to hold accountable for its conclusions or reasoning. Third, designers of ML systems for PM may be subject to diverse and divergent interests and needs of multiple stakeholders, yet unaware of the associated ethical and values implications for design. These distinctive features of ML in PM could lead to difficulties in detecting misalignment of design with values, and to breakdown in responsibility for realignment. Because machine learning in the context of precision medicine is such a new phenomenon, we have very little understanding of actual practices, work processes and the specific contexts in which design decisions are made. Importantly, we have little knowledge about the influences and constraints on these decisions, and how they intersect with values and ethical principles. Although the field of machine learning for precision medicine is still in its formative stage, there is growing recognition that designers of AI systems have responsibilities to ask such questions about values and ethics. In order to ask these questions, designers must first be aware that there are values expressed by design. Yet, there are few practical options for designers to learn how to increase awareness. Our specific aims are: Aim 1 To map the current state of ML in PM by identifying and cataloging existing US-based ML in PM projects and by exploring a range of values expressed by stakeholders about the use of ML in PM through a combination of multi-method review, and interviews of key informants and stakeholders. Aim 2 To characterize decisions and rationales that shape ML in PM and explore whether and how developers perceive values as part of these rationales through interviews of ML developers and site visits. Aim 3 To explore the feasibility of using design rationale as a framework for increasing awareness of the existence of values, and multiple sources of values, in decisions about ML in PM through group-based exercises with ML developers from academic and commercial settings.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
